Peripheral Venous Catheter Trial: 3 Day Versus No Routine Change

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to investigate the effects of extending the dwell time of peripheral intravenous cannulas on clinical outcomes and cost.

Clinical Trial Description

Among hospitalized patients, intravenous therapy is the most common invasive procedure. It is associated with a phlebitis rate of between 1.1% and 63% and a central venous catheter related bacteremia rate of approximately 3.0%. Catheter related blood-stream infections have an attributable mortality rate of 12% to 25%. Factors thought to be associated with these complications include insertion techniques, catheter securement, type of catheter used, type of infusate and additives, post-insertion catheter care and length of time the catheter remains in place.

Current Centers of Disease Control Guidelines provide direction for intravenous therapy management including a recommendation that peripheral intravenous catheters should be re-sited every 72-96 hours. Data underpinning the recommendation was collected in 1992, over a decade ago. Since that time, there have been improvements in catheter design and composition, and prospective surveillance studies have demonstrated the safety of longer dwell times. To date, these observations have not been validated in adults, using randomized controlled trial methodology.

Re-siting intravenous cannulas causes discomfort to patients and has a high recurrent cost. The primary aim of the present study is to compare the rates of peripheral catheter-related blood stream infection, catheter-related local infection, phlebitis and obstruction between two groups of patients - those having routine catheter changes every 72 hours and those having catheter changes only when clinically indicated.

Specific hypotheses:

That changing intravenous peripheral catheters when indicated by clinical signs compared to changing intravenous catheters every 3 days reduces the incidence of intravenous catheter related morbidity. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Phlebitis

Clinical Trial Details

NCT number	NCT00103636
Study type	Interventional
Source	Royal Brisbane and Women's Hospital
Contact
Status	Active, not recruiting
Phase	Phase 2/Phase 3
Start date	March 2004
Completion date	December 2004

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00989599` - Use of Chamomilla Recutita in Phlebitis	Phase 3
Completed	`NCT05714137` - Reducing the Risk of Phlebitis From Peripheral Venous Catheter	N/A
Completed	`NCT02568670` - Removal Peripheral Intravenous Catheters According to Clinical Signs or Every 96 Hours: A Non Inferiority Study	N/A
Completed	`NCT00670540` - Epidemiology of Thromboembolism Disease: A Cohort Study	N/A
Recruiting	`NCT06030141` - Investigation of the Effect of Nigella Sativa Oil and Sesame Oil in Preventing Phlebitis	N/A
Completed	`NCT03193827` - In-line Filtration Reduces Postoperative Phlebitis.	N/A
Completed	`NCT04569474` - Peripheral IV Dressing and Phlebitis in Patients From Amazon	N/A
Completed	`NCT01943006` - Efficacy and Tolerability of Hirudoid Cream in Prophylaxis and Treatment Infusion Phlebitis	Phase 3
Terminated	`NCT00418470` - Prolonging the Duration of Peripheral Venous Catheters in Cystic Fibrosis People	Phase 4
Completed	`NCT05058053` - THE EFFECT OF COLD APPLICATION ON THE DEVELOPMENT OF PHLEBITIS IN PATIENTS RECEIVING INTRAVENOUS AMIODARONE TREATMENT.	N/A
Recruiting	`NCT06375850` - Effects of Topical Sesame Oil in the Prevention of Peripheral Venous Catheter Phlebitis: Clinical Trial.	N/A
Completed	`NCT01131754` - Heparin 100U/L for Prevention of PVC Complications	Phase 3
Not yet recruiting	`NCT05870449` - The Impact of Climate Environment in Different Latitudes on the Occurrence of PICC Complications	N/A
Suspended	`NCT01794767` - Normal Saline Versus Heparinized Solution Flush for Maintaining Patency of Peripheral Venous Catheters in Children	Phase 4
Completed	`NCT04817020` - Effect of Skin Antisepsis on Phlebitis	N/A
Completed	`NCT05226312` - Phlebitis Care and Warm Wet Application	N/A
Terminated	`NCT04218643` - Ultrasound-guided Peripheral Intravenous Catheter Insertion Technique	N/A
Not yet recruiting	`NCT04685031` - Ointment Therapy and Prevention of Cannulation-Induced Superficial Phlebitis	Phase 1/Phase 2
Completed	`NCT04127149` - Evaluation of Ultra-portable Ultrasound in General Practice	N/A
Completed	`NCT06216522` - The Effectiveness of Topical Sesame Oil in Preventing Phlebitis at IV Cannula Sites in Adults	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.